1
|
Franc S, Bensaid S, Schaepelynck P, Orlando L, Lopes P, Charpentier G. Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment. DIABETES & METABOLISM 2023; 49:101486. [PMID: 37858921 DOI: 10.1016/j.diabet.2023.101486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/18/2023] [Accepted: 09/29/2023] [Indexed: 10/21/2023]
Abstract
Many studies have clearly established that chronic psychosocial stress may sustainably worsen glycemic control in patients with type 1 diabetes mellitus (T1DMM), thus promoting diabetes complications. Chronic psychosocial stress may be due to: i) the long-term accumulation of stressful life events that require readjustment on the part of the individual (loosing friends, changing schools), and/or ii) exposure to severe chronic stressors (persistent difficulties and adversities of life). Whatever the reason, many studies have clearly established a positive correlation between chronic psychosocial stress and HbA1c levels. However, a small fraction of patients is minimally affected or not affected at all by chronic psychosocial stress. Conversely, positive life events can substantially improve glycemic control. Recent evidence suggests the existence of subpopulations that differ in personality traits, neurohormonal regulatory responses, and food intake behavior (increased or decreased). Better characterization of the clinical and neurohormonal differences between these subpopulations may help develop personalized treatment strategies in the future. In the near future, psychotherapeutic support and automated insulin delivery (AID) could alleviate chronic stress, prevent worsening glycemic control, and ease the burden of diabetes.
Collapse
Affiliation(s)
- Sylvia Franc
- French Center for Studies and Research on the Intensification of Diabetes Treatment, CERITD, Evry, France; Department of Diabetes and Endocrinology, South Francilien Hospital Centre, Corbeil-Essonnes, France.
| | - Samir Bensaid
- French Center for Studies and Research on the Intensification of Diabetes Treatment, CERITD, Evry, France
| | - Pauline Schaepelynck
- Department of Nutrition-Endocrinology-Metabolic Diseases, Pôle ENDO, APHM-Hôpital la Conception, Marseille, France
| | - Laurent Orlando
- French Center for Studies and Research on the Intensification of Diabetes Treatment, CERITD, Evry, France
| | - Philippe Lopes
- LBEPS, Laboratory of Exercise Biology for Performance and Health, Evry University, Evry-Courcouronnes, France
| | - Guillaume Charpentier
- French Center for Studies and Research on the Intensification of Diabetes Treatment, CERITD, Evry, France; Department of Diabetes and Endocrinology, South Francilien Hospital Centre, Corbeil-Essonnes, France
| |
Collapse
|
2
|
Lee SF, Li CP. Personality as a predictor of HbA1c level in patients with type 2 diabetes mellitus. Medicine (Baltimore) 2021; 100:e26590. [PMID: 34232208 PMCID: PMC8270580 DOI: 10.1097/md.0000000000026590] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Accepted: 06/17/2021] [Indexed: 01/04/2023] Open
Abstract
Type 2 diabetes mellitus (T2DM) is the most common type of diabetes, accounting for around 90% of all cases worldwide. One means to strengthen the prevention and treatment of diabetes is via changes in self-management and lifestyle behaviors. However, lifestyle and personal health behaviors are strongly influenced by personality traits, and thus personality may play a significant role in such aspects as medication compliance, exercise habits, blood glucose monitoring, diet control, and maintenance of an ideal body weight.In this study, we examined whether certain personality traits of patients with T2DM are correlated with higher glycohemoglobin (HbA1c) levels.A total of 214 participants with T2DM were recruited from an outpatient setting. χ2 test and logistic regression analyses with 5 models were employed.The OR for the "neuroticism" trait was 3.199 (95% CI = 1.228-8.331, P = .017), and those with this trait were 3.199 times more likely to have higher HbA1c levels than those with the "openness-extraversion" personality trait. This strong relationship between neuroticism and a higher HbA1c level was also evident in models 2, 3, 4, and 5. One-way ANOVA also indicated that the group with the neuroticism personality trait had significantly different mean fasting glucose, HbA1c, triglyceride, and high-density lipoprotein cholesterol levels.We found that a personality characterized by neuroticism is an independent predictor of higher HbA1c level in this study. We also found that people in the pre-contemplation and contemplation stages of exercise have higher HbA1c levels.
Collapse
Affiliation(s)
- Shu-Fen Lee
- Department of Nursing, Cardinal Tien College of Healthcare and Management, New Taipei
| | - Chih-Ping Li
- Department of Health Industry Management, Kainan University, Taoyuan, Taiwan
| |
Collapse
|
3
|
Chauvet-Gélinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebaï A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Vergès B. Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. DIABETES & METABOLISM 2018; 45:582-585. [PMID: 30476653 DOI: 10.1016/j.diabet.2018.11.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 11/13/2018] [Accepted: 11/14/2018] [Indexed: 10/27/2022]
Abstract
AIM Type A personality has been associated with increased survival in people with type 1 diabetes (T1D). Systemic low-grade inflammation may play a critical role, as suggested in recent reports, although the links between the inflammatory circulating transcriptome and Type A remain unknown. This prompted our exploration of the potential associations between Type A personality and c-Fos gene expression, a candidate gene closely linked to inflammatory processes, in T1D. METHODS Type A personality was assessed by Bortner questionnaire in patients with T1D, and two subscales - 'speed' and 'competitiveness' - were used to measure these specific dimensions of Type A. Expression of the c-Fos gene was assessed by a quantitative real-time polymerase chain reaction technique. RESULTS This pilot study included 20 men with T1D. Multivariable analyses showed an independent inverse association between Type A competitiveness score and c-Fos expression, while a regression model adjusted for age, body mass index and HbA1c levels revealed a significant inverse relationship between c-Fos transcripts and Type A competitiveness (P = 0.003). CONCLUSION This strong association between Type A competitiveness and reduced c-Fos expression is in line with recent data suggesting a psychobiological influence of the Type A profile in T1D via inflammatory pathways.
Collapse
Affiliation(s)
- J-C Chauvet-Gélinier
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France
| | - A-L Mosca-Boidron
- Laboratoire de génétique chromosomique et moléculaire, plateforme de biologie hospitalo-universitaire, CHU de le Bocage, Dijon, France
| | - C Lemogne
- Université Paris Descartes, Sorbonne Paris Cité, faculté de médecine, 75006 Paris, France; AP-HP, hôpitaux universitaires Paris Ouest, service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, 75015 Paris, France; Inserm, centre for psychiatry and neuroscience, U894, 21000 Paris, France
| | - S Ragot
- Laboratoire de génétique chromosomique et moléculaire, plateforme de biologie hospitalo-universitaire, CHU de le Bocage, Dijon, France
| | - N Forestier
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France
| | - D Callegarin
- Laboratoire de génétique chromosomique et moléculaire, plateforme de biologie hospitalo-universitaire, CHU de le Bocage, Dijon, France
| | - C Allard
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France
| | - A Rebaï
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France
| | - B Bouillet
- Department of endocrinology and metabolic diseases, university hospital CHU de Le Bocage, 2, boulevard Maréchal de Lattre de Tassigny, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France
| | - E Ponavoy
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France
| | - I Simoneau
- Department of endocrinology and metabolic diseases, university hospital CHU de Le Bocage, 2, boulevard Maréchal de Lattre de Tassigny, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France
| | - J-M Petit
- Department of endocrinology and metabolic diseases, university hospital CHU de Le Bocage, 2, boulevard Maréchal de Lattre de Tassigny, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France
| | - G Bondolfi
- Service de psychiatrie de liaison et d'intervention de crise, hôpitaux universitaires de Genève, Geneva, Switzerland
| | - P Callier
- Laboratoire de génétique chromosomique et moléculaire, plateforme de biologie hospitalo-universitaire, CHU de le Bocage, Dijon, France
| | - B Trojak
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France
| | - B Bonin
- Psychiatry unit, department of neurosciences, university hospital, CHU de Le Bocage, Bâtiment Marion, 14, rue Gaffarel, 21000 Dijon, France; Laboratoire de psychopathologie et de psychologie médicale (IFR 100), université de Bourgogne-Franche-Comté, 21000 Bourgogne-Franche-ComtéFrance
| | - B Vergès
- Department of endocrinology and metabolic diseases, university hospital CHU de Le Bocage, 2, boulevard Maréchal de Lattre de Tassigny, 21000 Dijon, France; Inserm LNC-UMR 1231, 21000 Dijon, France.
| |
Collapse
|